The U.S. Food and Drug Administration (FDA) recently granted temporary importation of TEGLUTIK (riluzole 5 mg/mL oral suspension) into the United States.  To mitigate the critical and ongoing shortage of FDA-approved Tiglutik (riluzole oral suspension, 50 mg/10 mL) in the United States, the FDA recently permitted temporary importation of TEGLUTIK from the United Kingdom. Marketed … Read more

The U.S. Food and Drug Administration (FDA) recently granted temporary importation of TEGLUTIK (riluzole 5 mg/mL oral suspension) into the United States. To mitigate the critical and ongoing shortage of FDA-approved Tiglutik (riluzole oral suspension, 50 mg/10 mL) in the United States, the FDA recently permitted temporary importation of TEGLUTIK from Spain. TEGLUTIK is both … Read more

The U.S. Food and Drug Administration (FDA) recently granted temporary importation of TEGLUTIK (riluzole 5 mg/mL oral suspension) into the United States. To mitigate the critical and ongoing shortage of FDA-approved Tiglutik (riluzole oral suspension, 50 mg/10 mL) in the United States, the FDA recently permitted temporary importation of TEGLUTIK from Greece. Marketed by Italfarmaco … Read more

ITF Pharma, Inc. (“ITF”) has changed the company name to EDW Pharma, Inc. (“EDW”). The name change was effective November 1, 2023. EDW remains the parent company of both Womens Choice Pharmaceuticals, LLC and Edwards Pharmaceuticals, Inc. In addition, effective November 1, 2023, EDW moved the company’s corporate headquarters from Berwyn, PA to Paoli, PA. … Read more